top of page
Rear View of Young Woman
ToraBolic Logo_edited.png

OVERVIEW

TORABOLIC® is a 100% naturally derived, highly purified and patented bioactive proven by rigorous
pre-clinical and clinical data to reduce body fat, increase lean muscle mass thereby creating perfect conditions for improving body composition and strength. TORABOLIC® is designed for both men and women.

KEY FEATURES

  • Clinically proven in 2 human clinical studies

  • Patented composition and usage

  • Established safety with published toxicology studies

  • GRAS affirmed

  • ‘Informed Ingredient’ certified

  • ‘Strong Science’ certified

  • California Proposition 65 compliant

  • ETO compliant for European markets

  • 100% naturally derived with no excipients

  • Allergen Free

  • Gluten Free

To use these best in class Raw Ingredients in your masterpieces, Call Dr. Tim Harrigan at (520) 395-5156 or e-mail our team: Info@SynWellness.com​

APPLICATIONS

TORABOLIC® offers excellent stability across a range of delivery forms including tablets, capsules, gummies, powders, beverages, and functional foods.

Pre-Clinical Studies

  • TORABOLIC® was evaluated in mice fed with High Fat Diet (3)

  • TORABOLIC® for induction of AMPK production in adipocytes (4) 

  • TORABOLIC® and it’s protective effects on mitochondria (3)

  • TORABOLIC® as an inverse antagonist of CB1

  • TORABOLIC® has been studied in rat models for Letrozole induced PCOS (5)

  • TORABOLIC® prevents accumulation of fat mass around organs and reduction in cholesterol and triglycerides

  • TORABOLIC® can activate AMPK which leads to the reduction of lipid contents in adipocytes

  • TORABOLIC® prevents oxidative stress and protects mitochondrial health

  • TORABOLIC® was found to be inverse agonist with IC50 = 168.3 µg/mL (0.2103 mM)

  • TORABOLIC® was shown to be exerting protective effects in PCOS.

Clinical Studies

CLINICAL STUDY #1
Double-blind, randomized Placebo controlled study on forty-nine males to see effects of TORABOLIC® undergoing resistance training.

​

RESULT

  • Significant increase in lean mass after 8 weeks.

  • Significant decrease in body fat percentage after 8 weeks.

CLINICAL STUDY #2

A double-blind, placebo-controlled study investigating efficacy and safety of TORABOLIC® on various fat mass related parameters in females

​

RESULT

  • Significant reduction in skin fold thickness around the waist

  • Significant reduction in skin fold thickness around the suprailia region

  • Significant reduction in fat mass percentage

CLINICAL STUDY #3

A double-blind placebo-controlled study in 66 overweight females to study efficacy of TORABOLIC® for reduction of body fat percentage.

​

RESULT

  • Study in process. Expected to be completed by July 2025

CERTIFICATION

Screenshot 2025-08-17 at 10.39.56 AM.png
Screenshot 2025-08-17 at 10.40.08 AM.png
Screenshot 2025-08-17 at 10.40.12 AM.png
Screenshot 2025-08-17 at 10.40.22 AM.png
Screenshot 2025-08-17 at 10.40.29 AM.png
Screenshot 2025-08-17 at 10.40.35 AM.png
Screenshot 2025-08-17 at 10.40.43 AM.png
Screenshot 2025-08-17 at 11.33.17 AM.png

REFERENCES

1.) Deshpande P, Mohan V, Thakurdesai P. Preclinical safety evaluation of low molecular weight galactomannans based standardized fenugreek seeds extract. Excli Journal.
2016 Jul 13;15:446.
2.) Deshpande PA, Mohan V, Pore MP, Gumaste S, Thakurdesai PA. Prenatal developmental toxicity evaluation of low molecular weight galactomannans based standardized
fenugreek seed extract during organogenesis period of pregnancy in rats. Int. J. Pharm. Pharm. Sci. 2016 May 1;8(5):248-53.
3.) Kandhare AD, Bandyopadhyay D, Thakurdesai PA. Low molecular weight galactomannans-based standardized fenugreek seed extract ameliorates high-fat diet-induced
obesity in mice via modulation of FASn, IL-6, leptin, and TRIP-Br2. RSC advances. 2018;8(57):32401-16.
4.) Cheng CY, Yang AJ, Ekambaranellore P, Huang KC, Lin WW. Anti-obesity action of INDUS810, a natural compound from Trigonella foenum-graecum: AMPK-dependent
lipolysis effect in adipocytes. Obesity Research & Clinical Practice. 2018 Nov 1;12(6):562-9.
5.) Aswar, M. K., Deshpande, U. V. & Aswar, U. (2021). Galactomannan Restore Letrozole Induced Polycystic Ovarian Syndrome (PCOS) in Rat Model. American Journal of
Pharmacology and Toxicology, 16(1), 25-32. https://doi.org/10.3844/ajptsp.2021.25.32
6.) Poole C, Bushey B, Foster C, Campbell B, Willoughby D, Kreider R, Taylor L, Wilborn C. The effects of a commercially available botanical supplement on strength, body
composition, power output, and hormonal profiles in resistance-trained males. Journal of the International Society of Sports Nutrition. 2010 Dec;7:1-9.
7.) Deshpande PO, Bele V, Joshi K, Thakurdesai PA. Effects of low molecular weight galactomannans based standardized fenugreek seed extract in subjects with high fat mass:
A randomized, double-blind, placebo-controlled clinical study. Journal of Applied Pharmaceutical Science. 2020 Jan 3;10(1):062-9

*Disclaimer: These statements have not been evaluated by the food and drug administration.

This product is not intended to diagnose, treat, cure, or prevent any disease.

bottom of page